Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT alone vs IMRT plus concurrent chemoradiotherapy in stage II–III nasopharyngeal carcinoma
ChiCTR-IIR-16010191Phase 2Not yet recruiting
- Sponsor
- 651 East Dongfeng Road, East, Guangzhou, China
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by 651 East Dongfeng Road, East, Guangzhou, China. Primary endpoint: Progression-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-IIR-16010191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16010191.